Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients
Petronela Ancuta, Anupa Kamat, Kevin J Kunstman, Eun-Young Kim, Patrick Autissier, Alysse Wurcel, Tauheed Zaman, David Stone, Megan Mefford, Susan Morgello, Elyse J Singer, Steven M Wolinsky, Dana Gabuzda, Petronela Ancuta, Anupa Kamat, Kevin J Kunstman, Eun-Young Kim, Patrick Autissier, Alysse Wurcel, Tauheed Zaman, David Stone, Megan Mefford, Susan Morgello, Elyse J Singer, Steven M Wolinsky, Dana Gabuzda
Abstract
Elevated plasma lipopolysaccharide (LPS), an indicator of microbial translocation from the gut, is a likely cause of systemic immune activation in chronic HIV infection. LPS induces monocyte activation and trafficking into brain, which are key mechanisms in the pathogenesis of HIV-associated dementia (HAD). To determine whether high LPS levels are associated with increased monocyte activation and HAD, we obtained peripheral blood samples from AIDS patients and examined plasma LPS by Limulus amebocyte lysate (LAL) assay, peripheral blood monocytes by FACS, and soluble markers of monocyte activation by ELISA. Purified monocytes were isolated by FACS sorting, and HIV DNA and RNA levels were quantified by real time PCR. Circulating monocytes expressed high levels of the activation markers CD69 and HLA-DR, and harbored low levels of HIV compared to CD4(+) T-cells. High plasma LPS levels were associated with increased plasma sCD14 and LPS-binding protein (LBP) levels, and low endotoxin core antibody levels. LPS levels were higher in HAD patients compared to control groups, and were associated with HAD independently of plasma viral load and CD4 counts. LPS levels were higher in AIDS patients using intravenous heroin and/or ethanol, or with Hepatitis C virus (HCV) co-infection, compared to control groups. These results suggest a role for elevated LPS levels in driving monocyte activation in AIDS, thereby contributing to the pathogenesis of HAD, and provide evidence that cofactors linked to substance abuse and HCV co-infection influence these processes.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235–239.
- Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med. 2006;12:289–295.
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371.
- Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotoxin Res. 2003;9:101–107.
- Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol. 1995;25:3418–3424.
- Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997;349:692–695.
- Gartner S. HIV infection and dementia. Science. 2000;287:602–604.
- Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today. 1996;17:424–428.
- Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol. 2001;69:11–20.
- Amirayan-Chevillard N, Tissot-Dupont H, Capo C, Brunet C, Dignat-George F, et al. Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. Clin Exp Immunol. 2000;120:107–112.
- Triques K, Stevenson M. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol. 2004;78:5523–5527.
- Almodovar S, Del CCM, Maldonado IM, Villafane R, Abreu S, et al. HIV-1 infection of monocytes is directly related to the success of HAART. Virology. 2007;369:35–46.
- Zhu T, Muthui D, Holte S, Nickle D, Feng F, et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol. 2002;76:707–716.
- Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol. 2003;21:21.
- Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, et al. Circulating proviral HIV DNA and HIV-associated dementia. Aids. 2005;19:45–52.
- Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007;178:6581–6589.
- Ancuta P, Kunstman KJ, Autissier P, Zaman T, Stone D, et al. CD16+ monocytes exposed to HIV promote highly efficient viral replication upon differentiation into macrophages and interaction with T cells. Virology. 2006;344:267–276.
- Ancuta P, Autissier P, Wurcel A, Zaman T, Stone D, et al. CD16+ Monocyte-Derived Macrophages Activate Resting T Cells for HIV Infection by Producing CCR3 and CCR4 Ligands. J Immunol. 2006;176:5760–5771.
- McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol. 2003;9:205–221.
- Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69–81.
- Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988–994.
- Williams K, Westmoreland S, Greco J, Ratai E, Lentz M, et al. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest. 2005;115:2534–2545.
- McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3–10.
- Cherner M, Cysique L, Heaton RK, Marcotte TD, Ellis RJ, et al. Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol. 2007;13:23–28.
- Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med. 2003;197:1701–1707.
- Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417:95–98.
- Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol. 2001;75:10073–10089.
- Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol. 2006;80:1156–1164.
- Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis. 2005;41:1027–1034.
- Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev. 2003;16:209–219.
- Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res. 2002;8:319–327.
- Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology. 2007;133:1627–1636.
- Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196:361–370.
- Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. Aids. 2006;20:1591–1595.
- Morgello S. The nervous system and hepatitis C virus. Semin Liver Dis. 2005;25:118–121.
- Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–217.
- Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584–1589.
- Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. Aids. 2007;21:1915–1921.
- Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–759.
- Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–1433.
- Cohen IR, Norins LC. Natural human antibodies to gram-negative bacteria: immunoglobulins G, A, and M. Science. 1966;152:1257–1259.
- Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580–1587.
- Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med. 2004;200:587–599.
- Van Marle G, Rourke SB, Zhang K, Silva C, Ethier J, et al. HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. Aids. 2002;16:1905–1914.
- Ferrier L, Berard F, Debrauwer L, Chabo C, Langella P, et al. Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents Desamino-D-arg8-vasopressin (DDAVP), unlike ethanol, has no effect on a boring visual vigilance task in humans Thiopentone pharmacokinetics in patients with chronic alcoholism. Am J Pathol. 2006;168:1148–1154.
- Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des. 2002;8:995–1005.
- Peng X, Cebra JJ, Adler MW, Meissler JJ, Jr, Cowan A, et al. Morphine inhibits mucosal antibody responses and TGF-beta mRNA in gut-associated lymphoid tissue following oral cholera toxin in mice. J Immunol. 2001;167:3677–3681.
- Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412–420.
- Hutchinson SJ, Brettle RP, Gore SM. Predicting survival in AIDS: refining the model. Qjm. 1997;90:685–692.
- Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, et al. Variable progression of HIV-associated dementia. Neurology. 1998;50:1814–1820.
- Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265–273.
- Davidson DJ, Currie AJ, Bowdish DM, Brown KL, Rosenberger CM, et al. IRAK-4 mutation (Q293X): rapid detection and characterization of defective post-transcriptional TLR/IL-1R responses in human myeloid and non-myeloid cells. J Immunol. 2006;177:8202–8211.
- Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr, Medzhitov R, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002;110:191–202.
- Chapoval AI, Kamdar SJ, Kremlev SG, Evans R. CSF-1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: a potential pathway that regulates the severity of gram-negative infections. J Leukoc Biol. 1998;63:245–252.
- Asakura E, Yamauchi T, Umemura A, Hanamura T, Tanabe T. Intravenously administered macrophage colony-stimulating factor (M-CSF) specifically acts on the spleen, resulting in the increasing and activating spleen macrophages for cytokine production in mice. Immunopharmacology. 1997;37:7–14.
- Rankine EL, Hughes PM, Botham MS, Perry VH, Felton LM. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur J Neurosci. 2006;24:77–86.
- Kusdra L, McGuire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. Aids. 2002;16:31–38.
- Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99:13795–13800.
- Gartner S, Liu Y. Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol. 2002;8:69–75.
- Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis. 2001;184:699–706.
- Lien E, Aukrust P, Sundan A, Muller F, Froland SS, et al. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92:2084–2092.
- Zhou H, Lapointe BM, Clark SR, Zbytnuik L, Kubes P. A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol. 2006;177:8103–8110.
- Xaio H, Banks WA, Niehoff ML, Morley JE. Effect of LPS on the permeability of the blood-brain barrier to insulin. Brain Res. 2001;896:36–42.
- Shen Y, Rudnik J, Cassol S, Drouin J, Cameron W, et al. Blood monocytes from most human immunodeficiency virus type 1-infected patients do not carry proviral DNA. Clin Diagn Lab Immunol. 1994;1:531–537.
Source: PubMed